- 7Oct, 2026
This article was originally published on drugdeliveryleader.com. A conversation between TAXIS Pharmaceuticals’ Chief Scientific Officer, Ajit Parhi; and Life Science Connect’s Michelle Raley Antibiotic resistance is not only a matter of discovering new therapeutic agents. It also requires delivering those agents to the right pathogen, [...]
From Designation to Differentiation: What QIDP Signals for TAXIS and the Future of Antimicrobial Innovation
Antimicrobial resistance (AMR) is one of the most urgent and complex challenges in modern medicine. As existing antibiotics lose effectiveness, the need for novel therapies — and the infrastructure to support their development — has never been greater. The FDA’s Qualified Infectious Disease Product (QIDP) [...]
Innovation Alone Will Not Solve Antimicrobial Resistance
Discussions around antimicrobial resistance (AMR) often focus on the urgent need for new antibiotics. And while therapeutic innovation remains essential, the long-term challenge of AMR extends beyond drug discovery alone. Developing effective treatments is only one part of a much larger healthcare infrastructure problem involving [...]
- 10Jun, 2026
Why Antimicrobial Resistance Is Emerging as One of Healthcare’s Most Important Investment Priorities
Antimicrobial resistance (AMR) is often discussed as a future public health concern, but for healthcare systems, clinicians, and patients around the world, its impact is already measurable. Resistant infections are increasing the complexity and cost of care, limiting treatment options, and placing growing pressure on [...]
- 11May, 2026
Miami, FL – May 26, 2026 — TAXIS Pharmaceuticals, a clinical-stage company developing investigational anti-resistance therapies to address antimicrobial resistance (AMR), today announced that its scientific team will present preclinical data from two investigational antibiotic development programs addressing urgent AMR threats at the upcoming American [...]
- 11May, 2026
Miami, FL – May 12, 2026 — TAXIS Pharmaceuticals, a clinical-stage company developing investigational anti-resistance therapies to address antimicrobial resistance (AMR), today announced the publication of preclinical data in the peer-reviewed journal Antibiotics describing TXA11114, an investigational indole carboxamide efflux pump inhibitor (EPI) designed to [...]
